Full-Time
Senior Software Engineer
System Infrastructure
Posted on 12/30/2023
GRAIL
1,001-5,000 employees
Blood tests for early cancer detection
No salary listed
Senior
Menlo Park, CA, USA
Hybrid work environment
- BS/BA with 5+ years or Masters with 2+ years of experience
- Proficiency in building and supporting highly scalable systems on AWS
- Strong expertise in general-purpose programming languages such as Go, Python, Java, or JavaScript
- Experience with distributed computing concepts like cluster computing, caching, and fault tolerance
- Exceptional logical reasoning and analytical skills
- Detail-oriented approach in communication and engineering practices
- Experience designing simple, secure software solutions
- Strong written and verbal communication skills
- Experience with GRPC
- Experience with Infrastructure as Code (Terraform)
- Experience with Gitlab CI/CD pipelines
- Familiarity with next-generation sequencing, computational biology, or related fields
- Design and develop robust, scalable, and efficient software systems for large-scale computation in cancer detection while adhering to security and compliance practices
- Utilize GRAIL tools and libraries to iterate quickly on novel algorithms and analyses
- Work in a multi-disciplinary environment, ensuring software quality and operational excellence through rigorous testing and code reviews
- Contribute to open-source projects like Reflow, enhancing distributed, incremental data processing capabilities
GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages. The company uses high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning techniques to extract important information for early cancer detection. GRAIL's products are primarily sold to healthcare providers and research institutions, helping them screen patients for early signs of cancer, which can lead to better treatment outcomes. Unlike many competitors, GRAIL's approach is backed by large-scale clinical studies, ensuring the reliability of its tests. The company's goal is to reduce global cancer mortality by enabling early diagnosis when treatment is most effective.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$9.8B
Headquarters
Menlo Park, California
Founded
2016
Simplify's Take
What believers are saying
- GRAIL's Galleri test revenue grew 52% year-over-year to $25.4 million.
- Partnership with Function Health expands Galleri test accessibility to 400,000+ members.
- GRAIL's cash balance of $853.6 million provides financial stability until 2028.
What critics are saying
- Increased competition from Thrive and Freenome could impact GRAIL's market share.
- High cost of Galleri test may limit accessibility and adoption.
- Potential ethical concerns over genetic data handling could lead to public distrust.
What makes GRAIL unique
- GRAIL uses high-intensity sequencing for early cancer detection.
- The Galleri test screens for over 50 types of cancers with one blood draw.
- GRAIL's targeted methylation-based platform supports multi-cancer early detection.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.
Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.
Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.
Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↑ 1%MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
GRAIL to present at Jefferies Global Healthcare Conference 2025.
NEW YORK - Grail said on Monday that it has partnered with Athenahealth to integrate ordering of Grail's Galleri multi-cancer early detection (MCED) test into the AthenaCoordinator Core laboratory ordering service software.
MENLO PARK, Calif., Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m. ET.Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection TestingMENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection (MCED) testing.PRO assessment was conducted for eligible PATHFINDER study participants with either a cancer signal detected (CSD) or no cancer signal detected (NCSD) over a 12-month follow-up period. In the PATHFINDER study, general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the Galleri® test, and intent towards guideline-recommended screening and repeat MCED testing were assessed. Three instruments used to assess PRO included an adapted Multidimensional Impact of Cancer Risk Assessment (MICRA) for distress, uncertainty and positive experience at MCED test result disclosure, PRO Measurement Information System (PROMIS) Anxiety short-form for anxiety symptoms, the Short Form 12-Item Health Survey (SF-12v2) for health-related quality of life, and a satisfaction questionnaire."Previous studies have shown that there is a temporary increase in anxiety symptoms after cancer screening, particularly for those with a test result indicating they may have cancer," said Lincoln Nadauld, MD, lead author of the study and was vice president, chief of Precision Health & Academics at Intermountain Health during the PATHFINDER study and currently CEO at Culmination Bio, Inc